Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s00415-023-11935-4.pdf
Reference35 articles.
1. Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies. JAMA Neurol 77:184–191. https://doi.org/10.1001/jamaneurol.2019.3365
2. Farez MF, Correale J, Armstrong MJ et al (2019) Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 93:584–594. https://doi.org/10.1212/WNL.0000000000008157
3. Simpson-Yap S, De Brouwer E, Kalincik T et al (2021) Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97:e1870–e1885. https://doi.org/10.1212/WNL.0000000000012753
4. Louapre C, Ibrahim M, Maillart E et al (2022) Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 93:24–31. https://doi.org/10.1136/jnnp-2021-326904
5. Thornton JR, Harel A (2020) Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab. Mult Scler Relat Disord 44:102341. https://doi.org/10.1016/j.msard.2020.102341
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination;Vaccines;2024-08-19
2. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11
3. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?;Multiple Sclerosis and Related Disorders;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3